Skip to main content
Sirio Pharma Co., Ltd. logo

Sirio Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 300791 ISIN · CNE100003NB0 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,177 across all filing types
Latest filing 2025-12-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300791

About Sirio Pharma Co., Ltd.

https://www.siriopharma.com

Sirio Pharma Co., Ltd. is a global contract development and manufacturing organization (CDMO) specializing in dietary supplements and nutraceuticals. The company provides comprehensive services encompassing product formulation, manufacturing, and packaging. Its portfolio includes diverse delivery formats such as softgels, gummies, tablets, hard capsules, powders, and oral liquids. Sirio Pharma emphasizes innovation in delivery systems, offering specialized solutions like plant-based softgels and advanced probiotic formulations. The organization adheres to rigorous quality management systems and maintains multiple international certifications to meet global regulatory standards. Serving an international clientele, the company supports health and wellness brands through scalable production capacities and integrated supply chain solutions.

Recent filings

Filing Released Lang Actions
关于2025年限制性股票激励计划预留授予部分限制性股票授予登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the completion of the registration of a reserved grant of restricted stock under the company's 2025 restricted stock incentive plan. It includes specifics about the number of shares granted, the grant price, the number of recipients, the approval process by the board and shareholders, performance conditions, accounting treatment, and legal opinions. The document is a formal announcement of a share-based incentive plan grant and related share capital changes, not a full financial report or earnings release. It is not a proxy statement, nor a remuneration report, but rather a capital/financing update related to share issuance under an incentive plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7470 characters) and content confirm it is a substantive announcement, not just a brief notice or report publication announcement.
2025-12-04 Chinese
2025年第三季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (410 characters) indicating that the company has approved and will disclose its 2025 third quarter report on a regulatory website. It does not contain the actual financial data or the full report itself, but rather informs investors about the availability of the report. According to the MENU VS MEAL RULE, this is a report publication announcement, not the report itself.
2025-10-28 Chinese
第四届董事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from the company仙乐健康科技股份有限公司 regarding the approval of the 2025 third quarter report. It includes details about the board meeting, voting results, and references the third quarter report but does not contain the actual financial statements or substantive financial data itself. The document length is short (976 characters) and it states that the detailed report is available on the regulatory website. This fits the pattern of a Regulatory Filing (RNS) rather than the actual Interim/Quarterly Report (IR).
2025-10-28 Chinese
关于举行2025年第三季度网上业绩说明会的公告
Call Transcript Classification · 90% confidence The document is an announcement about holding a 2025 third quarter online earnings conference call (业绩说明会). It references the prior disclosure of the 2025 third quarter report but does not contain the report itself or detailed financial data. It invites investors to participate in the call and submit questions. The document length is short (822 characters), and it serves as a notice for an upcoming earnings call event rather than the call transcript or the quarterly report itself. Therefore, it fits best as a Call Transcript (CT) announcement or an Investor Presentation (IP) announcement. However, since it is specifically about an earnings explanation meeting (业绩说明会), the best fit is Call Transcript (CT) category, which includes earnings calls with Q&A. Confidence is high due to clear keywords and context.
2025-10-28 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 年第三季度报告' which translates to '2025 Third Quarter Report'. It contains detailed financial data including income, profit, cash flow, assets, liabilities, shareholder information, and management changes. The presence of comprehensive financial statements such as consolidated balance sheets and detailed financial metrics for the quarter indicates this is a quarterly financial report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-28 Chinese
关于部分董事、高级管理人员减持股份计划期限届满暨实施结果的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the expiration of a share reduction plan by certain directors and senior management, detailing the actual share sales and compliance with relevant regulations. It includes specific shareholding changes by directors but does not contain financial statements or detailed financial performance data. The content focuses on insider share transactions by company directors and executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and it is not a report or a regulatory filing but a specific announcement of insider share transactions.
2025-10-24 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.